Tioga Cardiovascular, A Shifamed Portfolio Company, Closes $30M In Series C Financing
Amount Raised
$30 Million
Round Type
Series C
CampbellManufacturingBiotechnologyHealth CareMedical DeviceInvestors
Description
Tioga Cardiovascular, a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the first closing of its $30M Series C financing. Led by Cormorant Asset Management, with significant participation from The Capital Partnership, AMED Ventures, the PA MedTech VC Fund, and Shifamed angel investors, the financing will be used to continue product development, support pre-clinical testing, and initiate first-in-human use for the company's novel transseptal mitral valve replacement (TMVR) technology.
Who to call at Tioga Cardiovascular, and when
A new round usually means Tioga Cardiovascular is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tioga Cardiovascular raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tioga Cardiovascular, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tioga Cardiovascular. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tioga Cardiovascular raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Tioga Cardiovascular raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.